Clinical Trials on Antibody–drug conjugates (ADCs) are gaining significant attention as a promising class of targeted anticancer therapies. The journey of ADCs began with Mylotarg, developed by Pfizer, which received its first regulatory approval in 2000. However, concerns related to safety led to its withdrawal a decade later. Its subsequent […]
Clinical Trials on Antibody–Drug Conjugates: Key Challenges
